Flora Growth Corp Stock Price, News & Analysis

Flora Growth Corp. (NASDAQ: FLGC) held its 2024 Annual and Special Meeting of Shareholders, where several key proposals were voted on. Shareholders elected four directors to the Board and reappointed Davidson & Company LLP as auditors. They also approved an amendment to increase the number of shares issuable under the 2022 Incentive Compensation Plan from 950,000 to 2,500,000. Additionally, shareholders approved the grant of stock appreciation rights to the CEO and CFO, and the issuance of 635,363 shares to acquire the minority interest of TruHC Pharma GmbH. All proposals passed with significant majority support, demonstrating shareholder confidence in the company's direction and governance.

Flora Growth Corp. (NASDAQ: FLGC) reported Q2 2024 financial results, highlighting strategic acquisitions and partnerships. Key developments include:

1. Acquisition of TruHC Pharma GmbH in Germany for $6.4 million in shares.

2. Acquisition of Australian Vaporizers for $0.7 million in shares.

3. Joint venture with Althea Group Holdings to enter the U.S. beverages market.

4. Q2 2024 financial highlights:

• Net loss of $2.7 million, improved 94% year-over-year
• Cash used in operations of $0.3 million, improved 91% year-over-year
• Total operating expenses of $6.7 million
• Adjusted EBITDA loss of $2.8 million

The company also launched new products, entered distribution partnerships, and listed on the Frankfurt Stock Exchange.

Flora Growth Corp. (NASDAQ: FLGC) celebrates National CBD Day, highlighting the CBD industry's rapid growth and increasing acceptance. The market is projected to surpass $16 billion with a 40% CAGR since 2021. Key points include:

• Over 325,000 individuals employed in the U.S. CBD sector
• Widespread retail availability, including specialty stores and mainstream chains
• Increasing favorable regulations across states

Flora Growth leverages its JustCBD brand to contribute to the industry's growth, focusing on high-quality CBD products. CEO Clifford Starke emphasizes the company's alignment with the industry's trajectory of serving consumers, job creation, and advocating for sensible regulations.

Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) has announced its listing on the Frankfurt Stock Exchange (FSE) under the symbol '7301'. This strategic move aims to increase trading liquidity and facilitate investment from European investors. The FSE, one of the world's largest organized exchange-trading markets, offers Flora access to its electronic trading platform, XETRA, which is directly linked to major European financial hubs.

CEO Clifford Starke emphasized that this listing provides a pathway for new European investors to gain exposure to the company, in addition to enhancing liquidity and trading. The FSE's reach extends to key financial centers such as Switzerland, Luxembourg, Lichtenstein, and Monaco, potentially broadening Flora's investor base.

Flora Growth Corp. (NASDAQ: FLGC) has announced the launch of two new gummy products under its JustCBD brand. The new offerings include JustCBD+ Calm Gaba & L-Theanine Mixed Berry Gummies for stress management and relaxation, and JustCBD+ Sleep Magnesium and Melatonin Raspberry Gummies for improved sleep quality.

The Calm gummies combine Gaba and L-Theanine to help users manage stress, while the Sleep gummies utilize Magnesium and Melatonin to promote faster and deeper sleep. Both products feature appealing flavors to enhance the user experience. CEO Clifford Starke emphasized that these new products align with the company's mission to provide high-quality, effective solutions to enhance customers' lives.

Flora Growth Corp. (NASDAQ: FLGC) has completed the acquisition of Australian Vaporizers Pty The deal involved exchanging 550,000 Flora common shares, valued at $0.7 million based on the closing price on June 3, 2024. The transaction closed on June 4, 2024. Australian Vaporizers, founded in 2010, is among Australia's largest online retailers of vaporizers and related accessories. The company has sold over 92,000 units to more than 30,000 active customers through B2B and direct consumer channels. Flora's CEO, Clifford Starke, highlighted that the acquisition will enhance the company's bottom line and create synergies with existing brands, particularly Vessel Brand products in Australia.

Flora Growth Corp. (NASDAQ: FLGC) has partnered with Althea Group Holdings (ASX: AGH) to form Peak USA JV , a 50/50 joint venture targeting the U.S. cannabis-infused beverages market. Each company contributed $250,000 in operating capital to Peak USA. This collaboration merges Flora's expertise in brand development and sales with Althea's advanced cannabis beverage processing capabilities. The U.S. cannabis beverages segment currently represents 1% to 3% of the market, indicating significant growth potential. With cannabis overtaking alcohol in daily use among first-time users, the joint venture aims to offer a compelling alternative to alcohol. Peak USA will navigate regulatory challenges and leverage combined strengths to establish a strong market presence and drive mutual growth.

Flora Growth's Vessel Brand has launched the second-generation Compass Rise, a high-quality vape device. Built with a nearly indestructible metal frame, enhanced heat settings, and top-tier ergonomics, Compass Rise aims to elevate the vaping experience for discerning customers. The product is now available on Vessel's website, through Multi-State Operators, and select retailers.

In Q1 2024, Vessel achieved a gross profit margin of 39% from $1.3 million in sales, with Compass products contributing 31% of total sales. Revenue was split evenly between direct-to-consumer and business-to-business sales, including significant contributions from MSOs.

On May 17, 2024, Flora Growth Corp (NASDAQ: FLGC) expressed support for President Joe Biden's decision to reschedule cannabis under U.S. federal law. CEO Clifford Starke emphasized Flora's focus on building brands both domestically and internationally, and highlighted the potential benefits of cannabis reform in the healthcare sector. The reclassification aims to move cannabis from Schedule I to Schedule III, allowing greater medical access in the U.S. Flora, with experience in European medical cannabis, looks forward to this potential market opportunity. The Justice Department will open a 60-day public comment period before finalizing the rule.